An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations

The current SARS-CoV-2 pandemic has high fatality rates and imposes increasingly severe social and economic impacts worldwide. Covid-19 patients with cardiovascular disease are at increased risk of death. They are very often treated with drugs targeting the renin-angiotensin-aldosterone system, where angiotensin converting enzyme (ACE) is of particularly importance. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) are standard therapies for high blood pressure and heart failure (HF) and currently prescribed to more than 25 Mio people in Germany alone (approx.
Source: Journal of Molecular and Cellular Cardiology - Category: Cytology Authors: Tags: Letter to the editor Source Type: research